We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tonix Pharmaceuticals has no tonic for cocaine intoxication, with the biopharma terminating a midstage trial for the condition amid poor trial enrollment. The investigational drug in question, TNX ...

Tonix Pharmaceuticals presented promising data on TNX-1700 for gastric and colorectal cancers, enhancing anti-PD1 therapy effectiveness in preclinical models. Tonix Pharmaceuticals has announced ...

CHATHAM, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and ...

Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered pig organs in xenotransplantation Establishes ...

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on ...

CHATHAM, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and ...

Tonix Pharmaceuticals (TNXP) announced a collaborative research agreement under which Tonix and Makana will study Tonix’s anti-CD40L monoclonal antibody candidate, TNX-1500, in combination with ...

Tonix Pharmaceuticals Stock Down 10.6 % TNXP stock opened at $15.64 on Friday. The firm has a market cap of $100.64 million, a PE ratio of 0.00 and a beta of 2.23. Tonix Pharmaceuticals has a one ...

A copy of the Company's presentation is available under the Scientific Presentations tab of the Tonix website at . The presentation titled,“TFF2-mediated CXCR4 partial agonism outperforms CXCR4 ...